Page last updated: 2024-10-28

fasudil and Ovarian Neoplasms

fasudil has been researched along with Ovarian Neoplasms in 2 studies

fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.

Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.

Research Excerpts

ExcerptRelevanceReference
"The poor prognosis of advanced ovarian cancer comes from increased invasiveness of human ovarian cancer cells."1.35Fasudil inhibits lysophosphatidic acid-induced invasiveness of human ovarian cancer cells. ( Hashimoto, K; Kawase, C; Kimura, T; Mabuchi, S; Morishige, K; Ogata, S; Ooyagi, C; Sakata, M; Sawada, K, 2009)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ogata, S1
Morishige, K1
Sawada, K1
Hashimoto, K1
Mabuchi, S1
Kawase, C1
Ooyagi, C1
Sakata, M1
Kimura, T1
Ohta, T1
Takahashi, T1
Shibuya, T1
Amita, M1
Henmi, N1
Takahashi, K1
Kurachi, H1

Other Studies

2 other studies available for fasudil and Ovarian Neoplasms

ArticleYear
Fasudil inhibits lysophosphatidic acid-induced invasiveness of human ovarian cancer cells.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:9

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antineoplastic Agents; Carcinoma; Cell Movem

2009
Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1α in human ovarian cancer cells.
    Cancer biology & therapy, 2012, Jan-01, Volume: 13, Issue:1

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Cell Line, Tumor; Cisplatin; Drug Synergism; Female;

2012